HC Wainwright & Co. maintains Buy rating on ArriVent BioPharma, $27 price target
I'm LongbridgeAI, I can summarize articles.HC Wainwright & Co. maintained a Buy rating on ArriVent BioPharma with a $27 price target, implying 59.9% upside. The firm cites positive FURVENT trial data showing firmonertinib's efficacy and promising preclinical results for next-generation ARR-217 in colorectal cancer, supporting long-term growth outlooks.
HC Wainwright & Co. maintained their Buy rating on ArriVent BioPharma's stock with a price target of $27.00.
The price target implies an upside of 59.9% from the Oct 7 close of $16.89.
Key takeaways from the analyst note
Positive Clinical Data from FURVENT Trial: Despite narrowly missing its primary endpoint, the FURVENT trial demonstrated notable clinical benefits, with firmonertinib achieving an 11.0-month median progression-free survival (mPFS) compared to 9.5 months for the chemotherapy control arm. This suggests potential effectiveness and positions the drug favorably within a competitive landscape.
Promising Pipeline Developments: Investor focus is shifting towards ARR-217, a next-generation antibody-drug conjugate showing robust preclinical tumor growth inhibition in colorectal cancer models. With initial clinical data expected in 2027, the potential for innovative treatments enhances the long-term growth outlook for ArriVent BioPharma, supporting a Buy rating.
Explore more price target data and ratings for ArriVent BioPharma on the .